P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE studyAndrés Yarur, Brian Bressler, M Bassel et al.|Journal of Crohn s and Colitis|2019Cited by 8
638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's DiseaseBrian Bressler, Gerassimos J. Mantzaris, Andrés Yarur et al.|The American Journal of Gastroenterology|2019Cited by 6
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVEGerassimos J. Mantzaris, Andrés Yarur, Brian Bressler et al.|Journal of Crohn s and Colitis|2020Cited by 4